Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

Key facts

Where
Amarillo, Bowling Green, Cary, Conroe, Dallas, Durham, Edinburg, El Paso, Flint, Fort Worth, Gilbert, Houston, Humble, La Mesa, Livonia, Macon, Miami Lakes, Niagara Falls, Ocoee, Omaha, Orchard Park, Palm Harbor, Phoenix, Sacramento, San Francisco, Sarasota, Sayre, Torrance, and Tucson, United StatesSee the 29 sites
Phase
Phase 2

Where in United States

  • Amarillo, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Bowling Green, KentuckyHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Cary, North CarolinaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Conroe, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Dallas, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Durham, North CarolinaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Edinburg, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • El Paso, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Flint, MichiganHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Fort Worth, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Gilbert, ArizonaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Houston, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Humble, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • La Mesa, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Livonia, MichiganHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Macon, GeorgiaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Miami Lakes, FloridaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Niagara Falls, New YorkHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Ocoee, FloridaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Omaha, NebraskaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Orchard Park, New YorkHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Palm Harbor, FloridaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Phoenix, ArizonaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Sacramento, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • San Francisco, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Sarasota, FloridaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Sayre, PennsylvaniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Torrance, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Tucson, ArizonaHospital not named in the registryContact: Victoria Lacasse, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Yarrow Bioscience, Inc.
Trial code
NCT07682896
Record updated
30 October 2026
Original description
This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.Read full original descriptionShow less

A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease

This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.

The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2.

Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.

Inclusion: Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment; Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening; Additional inclusion criteria are defined in the protocol.

Exclusion: Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy; Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening; Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening; History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit; Pregnant or lactating women; Additional exclusion criteria are defined in the protocol.

ClinicalTrials.gov NCT07682896